2nd Quarter - Report

340B HEALTH for 340B HEALTH

Firm
Client
Income
—
Expenses
$216,950
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program, FY18 LHHS Appropriations, Interim Final Rule Delaying Effective Dates of 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation

LobbyistCovered position, as disclosed
JEFFREY IRVING DAVIS —
KATHRYN DIBITETTO —
GREG DOGGETT —
TED SLAFSKY —
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.